Pediatric relapsed/refractory ALK+ anaplastic large cell lymphoma treatment and outcomes in the targeted drug era
Work
Year: 2025
Type: article
Abstract: Treatment options for patients with relapsed or refractory (R/R) anaplastic large cell lymphoma (ALCL) have increased in the era of targeted therapies such as brentuximab vedotin (BV) and Anaplastic L... more
Source: Blood Advances
Institutions Stanford University, Palo Alto University, Michigan United, Baylor College of Medicine, Seattle Children's Hospital +17 more
Cites:
Cited by:
Related to: 10
FWCI:
Citation percentile (by year/subfield):
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: gold
APC paid (est): $3,000